141 related articles for article (PubMed ID: 34137699)
1. [SARS-COV-2 infection in patients with hematological malignancies and transplants].
Herrera F; Bues F; Rojas R; Temporiti E; Videla C; Dupont J; Bonvehí P
Medicina (B Aires); 2021; 81(3):396-400. PubMed ID: 34137699
[TBL] [Abstract][Full Text] [Related]
2. Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies.
Jeyaraman P; Agrawal N; Bhargava R; Bansal D; Ahmed R; Bhurani D; Bansal S; Rastogi N; Borah P; Naithani R;
Transfus Apher Sci; 2021 Jun; 60(3):103075. PubMed ID: 33574010
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic COVID-19 with convalescent/postvaccination plasma in patients with hematologic malignancies.
Janssen M; Leo A; Wolf C; Stenzinger M; Bartenschlager M; Brandt J; Sauer S; Schmitt M; Dreger P; Schlenk RF; Denkinger CM; Müller-Tidow C
Int J Cancer; 2024 Aug; 155(4):618-626. PubMed ID: 38721724
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome.
Levy I; Lavi A; Zimran E; Grisariu S; Aumann S; Itchaki G; Berger T; Raanani P; Harel R; Aviv A; Lavi N; Zuckerman T; Shvidel L; Jarchowsky O; Ellis M; Herzog Tzarfati K; Koren-Michowitz M; Sherf Y; Levi I; Sofer O; Shpilberg O; Dally N; Suriu C; Braester A; Ben Barouch S; Leiba M; Goldstein D; Sarid N; Yeganeh S; Halloun J; Mittelman M; Tadmor T
Leuk Lymphoma; 2021 Dec; 62(14):3384-3393. PubMed ID: 34405767
[TBL] [Abstract][Full Text] [Related]
5. Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.
Magyari F; Pinczés LI; Páyer E; Farkas K; Ujfalusi S; Diószegi Á; Sik M; Simon Z; Nagy G; Hevessy Z; Nagy B; Illés Á
Ann Hematol; 2022 Oct; 101(10):2337-2345. PubMed ID: 35836007
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study.
Węcławek-Tompol J; Zakrzewska Z; Gryniewicz-Kwiatkowska O; Pierlejewski F; Bień E; Zaucha-Prażmo A; Zając-Spychała O; Szmydki-Baran A; Mizia-Malarz A; Bal W; Sawicka-Żukowska M; Kruk A; Ociepa T; Raciborska A; Książek A; Szczepański T; Peregud-Pogorzelski J; Krawczuk-Rybak M; Chaber R; Matysiak M; Wachowiak J; Irga-Jaworska N; Młynarski W; Dembowska-Bagińska B; Balwierz W; Matkowska-Kocjan A; Kazanowska B; Styczyński J; Ussowicz M
J Hematol Oncol; 2021 Oct; 14(1):163. PubMed ID: 34635137
[TBL] [Abstract][Full Text] [Related]
7. Charting a path forward: Promising outcomes of convalescent plasma therapy in the care of severely B-cell depleted patients with persistent COVID-19.
Inbar T; Dann EJ; Kerner O; Stern A
Transfusion; 2024 Mar; 64(3):443-448. PubMed ID: 38327238
[TBL] [Abstract][Full Text] [Related]
8. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
9. Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes.
Guo W; Zheng Y; Feng S
Front Cell Infect Microbiol; 2023; 13():1207225. PubMed ID: 37928188
[TBL] [Abstract][Full Text] [Related]
10. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.
Weinbergerová B; Demel I; Víšek B; Válka J; Čerňan M; Jindra P; Novák J; Stejskal L; Kovácsová F; Kabut T; Szotkowski T; Hájek R; Žák P; Cetkovský P; Král Z; Mayer J
Hematol Oncol; 2022 Apr; 40(2):280-286. PubMed ID: 35120267
[TBL] [Abstract][Full Text] [Related]
11. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies.
Civriz Bozdağ S; Cengiz Seval G; Yönal Hindilerden İ; Hindilerden F; Andıç N; Baydar M; Aydın Kaynar L; Toprak SK; Göksoy HS; Balık Aydın B; Demirci U; Can F; Özkocaman V; Gündüz E; Güven ZT; Özkurt ZN; Demircioğlu S; Beksaç M; İnce İ; Yılmaz U; Eroğlu Küçükdiler H; Abishov E; Yavuz B; Ataş Ü; Mutlu YG; Baş V; Özkalemkaş F; Üsküdar Teke H; Gürsoy V; Çelik S; Çiftçiler R; Yağcı M; Topçuoğlu P; Çeneli Ö; Abbasov H; Selim C; Ar MC; Yücel OK; Sadri S; Albayrak C; Demir AM; Güler N; Keklik M; Terzi H; Doğan A; Yegin ZA; Kurt Yüksel M; Sadri S; Yavaşoğlu İ; Beköz HS; Aksu T; Maral S; Erol V; Kaynar L; İlhan O; Bolaman AZ; Sevindik ÖG; Akyay A; Özcan M; Gürman G; Ünal Ş; Yavuz Y; Diz Küçükkaya R; Özsan GH
Turk J Haematol; 2022 Feb; 39(1):43-54. PubMed ID: 34521187
[TBL] [Abstract][Full Text] [Related]
12. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19.
Hueso T; Pouderoux C; Péré H; Beaumont AL; Raillon LA; Ader F; Chatenoud L; Eshagh D; Szwebel TA; Martinot M; Camou F; Crickx E; Michel M; Mahevas M; Boutboul D; Azoulay E; Joseph A; Hermine O; Rouzaud C; Faguer S; Petua P; Pommeret F; Clerc S; Planquette B; Merabet F; London J; Zeller V; Ghez D; Veyer D; Ouedrani A; Gallian P; Pacanowski J; Mékinian A; Garnier M; Pirenne F; Tiberghien P; Lacombe K
Blood; 2020 Nov; 136(20):2290-2295. PubMed ID: 32959052
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
15. Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19.
Biernat MM; Kolasińska A; Kwiatkowski J; Urbaniak-Kujda D; Biernat P; Janocha-Litwin J; Szymczyk-Nużka M; Bursy D; Kalicińska E; Simon K; Mazur G; Wróbel T
Viruses; 2021 Mar; 13(3):. PubMed ID: 33800528
[TBL] [Abstract][Full Text] [Related]
16. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma.
Karataş A; İnkaya AÇ; Demiroğlu H; Aksu S; Haziyev T; Çınar OE; Alp A; Uzun Ö; Sayınalp N; Göker H
Transfus Apher Sci; 2020 Oct; 59(5):102871. PubMed ID: 32694044
[TBL] [Abstract][Full Text] [Related]
17. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
Trials; 2021 May; 22(1):342. PubMed ID: 34001174
[TBL] [Abstract][Full Text] [Related]
18. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies.
Ferrari S; Caprioli C; Weber A; Rambaldi A; Lussana F
Leuk Lymphoma; 2021 Jun; 62(6):1490-1496. PubMed ID: 33461387
[TBL] [Abstract][Full Text] [Related]
19. Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study.
Lanza F; Monaco F; Ciceri F; Cairoli R; Sacchi MV; Guidetti A; Marchetti M; Massaia M; Arcaini L; Krampera M; Mohamed S; Gherlinzoni F; Mecucci C; Gentile M; Romano I; Venditti A; Ruggeri M; Ferrero D; Coviello E; Fabbri E; Corradini P; Passamonti F
Hematol Oncol; 2022 Dec; 40(5):857-863. PubMed ID: 35932208
[TBL] [Abstract][Full Text] [Related]
20. Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study.
Wu Y; Hong K; Ruan L; Yang X; Zhang J; Xu J; Pan S; Ren L; Chen L; Huang C; Shang Y
Virol Sin; 2020 Dec; 35(6):768-775. PubMed ID: 32865701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
